DENVER, June  23, 2026  (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological

NTHI

These Emerging Companies Are Racing Toward Major Catalysts

NeOnc's Abu Dhabi IND boosts NTHI near-term catalyst

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 NeOnc Technologies (NTHI) announced Abu Dhabi DOH IND for NEO100 across adult Phase 1–2 and pediatric pathways, expanding international development alongside UAE authorization for NEO212. The upcoming NEO100-01 Phase 2a readout by end-July 2026 could unlock additional regulatory pathways and valuation upside if data are positive. Investors should monitor the readout as a near-term catalyst.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Abu Dhabi DOH grants IND for NEO100 covering adult Phase 1–2.</li><li>NEO100-01 Phase 2a readout expected by end-July 2026.</li><li>NEO100 holds FDA Orphan Drug, Fast Track, Rare Pediatric Disease designations.</li><li>UAE authorizes NEO212; parallel development potential.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>NeOnc Technologies (NTHI): Main catalyst: Abu Dhabi IND for NEO100; Phase 2a readout end-July 2026; pediatric pathways.</li><li>Boundless Bio (BOLD): Transformational merger with Serapha Bio signals biotech M&amp;A activity; potential sentiment spillover.</li><li>Backblaze (BLZE): Five-year AI storage deal with CoreWeave highlights AI infrastructure demand.</li><li>HeartSciences (HSCS): Proposed merger with Fortitude Mining; indicates ongoing consolidation in tech/crypto-adjacent spaces.</li></ul>
 </section>

 <section data-block="category">
 <h3>Industry News</h3>
 Industry News: aggregates multiple biotech and tech catalysts; highlights near-term regulatory milestones and broader market context for innovative therapies.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>NEO100-01 Phase 2a readout due by end-July 2026; near-term catalyst.</li><li>Abu Dhabi IND expands international trial footprint for NEO100.</li><li>UAE NEO212 program approval supports parallel development.</li><li>Positive data could prompt regulatory discussions and potential valuation upside.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>DOH Abu Dhabi granted IND for NEO100 covering adult Phase 1–2 and pediatric pathways.</li><li>Phase 2a readout for NEO100-01 expected by end-July 2026.</li><li>NEO100 holds FDA Orphan Drug, Fast Track, Rare Pediatric Disease designations.</li><li>UAE authorized NEO212 program; allows parallel development.</li><li>Earlier UAE authorization for NEO212; parallel global development.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Bullish for NTHI over the next 1–3 quarters on the July 2026 Phase 2a readout.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points. NeOnc Technologies Approaches Major Clinical Catalyst NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NTHI">NTHI</a>) has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase 2 studies, while also establishing a pathway for pediatric development in recurrent and progressive high-grade gliomas. The development significantly expands NeOnc&#39;s international clinical footprint and follows the company&#39;s previously announced UAE authorization for its NEO212 program. The broader authorization potentially allows parallel advancement of multiple development stages while complementing ongoing U.S. regulatory progress. Investors appear particularly focused on the company&#39;s upcoming NEO100-01 Phase 2a readout, which NeOnc expects to report by the end of July 2026. NEO100 already holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, and management has indicated that positive data could support discussions involving additional regulatory pathways. High-grade gliomas remain among the most aggressive and difficult-to-treat brain cancers. NeOnc&#39;s intranasal delivery platform is designed to bypass the blood-brain barrier through non-invasive administration, a characteristic that differentiates the program from many traditional CNS treatment approaches. As the anticipated data release approaches, investors will be watching closely for evidence supporting further clinical advancement. Boundless Bio Reinvents Itself Through Transformational Merger Boundless Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BOLD">BOLD</a>) announced a major strategic shift through its proposed merger with privately held Serapha Bio, creating a new publicly traded company focused on gene-editing therapies for Alpha-1 Antitrypsin Deficiency (AATD). The transaction is accompanied by approximately $230 million in committed financing from a syndicate led by RTW Investments and RA Capital Management, providing what the companies believe will be sufficient funding into the second half of 2029. The financing is expected to support Phase 2 completion and Phase 3 initiation for Serapha&#39;s lead candidate, SERP-01. SERP-01 is an investigational in vivo base-editing therapy designed to correct the SERPINA1 E342K mutation responsible for severe forms of AATD. The therapy aims to simultaneously address both liver and lung manifestations of the disease through a single administration by restoring functional alpha-1 antitrypsin production while reducing toxic protein accumulation. The transaction also highlights continued investor enthusiasm surrounding next-generation genetic medicines. With backing from prominent healthcare investors and a planned Nasdaq listing under the proposed ticker &#34;AATD,&#34; the combined company enters the public markets with substantial capital resources and a focused development strategy targeting a significant unmet medical need. $335 Million AI Deal Ignites Backblaze as Data Storage Demand Explodes Backblaze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/BLZE">BLZE</a>) announced a five-year, multi-exabyte data storage agreement valued at approximately $335 million with CoreWeave, one of the fastest-growing AI cloud infrastructure providers in the market. The agreement positions Backblaze as a key storage provider supporting portions of CoreWeave&#39;s managed storage infrastructure as demand for AI computing capacity continues expanding globally. The partnership underscores a rapidly evolving reality within the AI ecosystem: compute power alone is no longer enough. Every stage of the AI lifecycle, from data preparation and model training to checkpointing, inference, and long-term storage, depends on the efficient movement and management of vast datasets. As organizations race to deploy increasingly sophisticated AI applications, the ability to store, retrieve, and manage data at scale has become a strategic competitive advantage. Under the agreement, Backblaze will provide HDD-based storage capacity supporting CoreWeave AI Object Storage, helping optimize data placement across performance tiers while preserving high-performance resources for the most demanding AI workloads. The integration allows customers to access expanded storage capabilities without modifying existing applications, potentially simplifying adoption for enterprises already operating within the CoreWeave ecosystem. Fortitude Mining Targets Public Markets Through HeartSciences Merger HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/HSCS">HSCS</a>) announced a proposed business combination with Fortitude Mining Holdings, a digital asset mining platform focused primarily on Zcash. Upon closing, the combined company is expected to operate under the Fortitude name and trade under the proposed Nasdaq ticker &#34;TUDE.&#34; Existing Fortitude owner Digital Currency Group is expected to hold approximately 95% of the combined company. Fortitude&#39;s model differs from many traditional mining operations through its emphasis on &#34;venture mining,&#34; which focuses on identifying and scaling high-conviction Proof-of-Work opportunities. The company currently maintains a significant presence within the Zcash ecosystem and operates a vertically integrated infrastructure platform that includes power assets, mining operations, and data-center capacity. The transaction reflects ongoing consolidation and evolution within digital asset markets as infrastructure-focused operators seek broader access to public capital. As institutional participation in digital assets continues developing, investors may increasingly focus on mining companies with differentiated operational models and scalable infrastructure footprints. About 24/7 Market News In today&#39;s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you&#39;re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact <a href="https://www.globenewswire.com/Tracker?data=oVQK-k2h3lDnBoHHS0yLPhn3nKFF94cU9BeUkmw7x99vbQKn3DX8wgGOwg1SEvAw-up3u4M_SG485wgHLzvzQFuv4HCdQ59Pc3TbBZ-yCSsKDiE6UbS4naVktXauP018" rel="nofollow" target="_blank">sales@247marketnews.com</a> to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory. This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.  For the full disclosure, please visit: <a href="https://www.globenewswire.com/Tracker?data=VYDfp1yN-qHPv5GFIbeyQP5WsfqPetqMFmN7YykkxdEZHQIAfFgawgD8xxv5oiPwoVR-rc5hoD5m-xkYMcDEfmrnmYgFh749px17unGnrY_m7BrsAEwUatGPSvRvExBhS8duO70gHNElhekC9I6khcriYyP00BZPkINPX0jdJbc=" rel="nofollow" target="_blank">https://go.247marketnews.com/nthi-disclosure/</a> For further information, please visit <a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw8avR0eOI86b0o6VhQl4mysKrWOA4n4M3cqPusqe-mRVy4BSmItHCDLbOArCOt6MGstCJKdpDDC--PaJq1ucCz0=" rel="nofollow" target="_blank">247marketnews.com</a>. Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures. CONTACT: 24/7 Market News <a href="https://www.globenewswire.com/Tracker?data=njA33JvyluBh0BCaW_qlDoUFsZWXtwJuMPefBHZQ8EbQhu1B8eCCKF7_bUoIUycBtavRsoNn-0YWf__gJNsDiME1eE7-6yHOtH6Jx9ZDT5MIpHw4FFFPfAUVCZ6mYdqW" rel="nofollow" target="_blank">Editor@247marketnews.com</a> Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company&#39;s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words &#34;intends,&#34; &#34;may,&#34; &#34;will,&#34; &#34;plans,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;projects,&#34; &#34;predicts,&#34; &#34;estimates,&#34; &#34;aims,&#34; &#34;believes,&#34; &#34;hopes,&#34; &#34;potential&#34; or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company&#39;s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company&#39;s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1MTE4MCM3Njc0MTI3IzIzMDQzNjM="></img> <img alt="" src="https://ml.globenewswire.com/media/OWIwMmRiNzQtNTY1MC00MTE1LWE5MTQtYmI1MWMxYzY2ODkyLTEzMTU5MTMtMjAyNi0wNi0yMy1lbg==/tiny/24-7-Market-News.png" referrerpolicy="no-referrer-when-downgrade"></img>

NeOnc Technologies (NTHI) announced Abu Dhabi DOH IND for NEO100 across adult Phase 1–2 and pediatric pathways, expanding international development alongside UAE authorization for NEO212. The upcoming NEO100-01 Phase 2a readout by end-July 2026 could unlock additional regulatory pathways and valuation upside if data are positive. Investors should monitor the readout as a near-term catalyst.

These Emerging Companies Are Racing Toward Major Catalysts

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News